Bausch Health Companies INC 8-K filings

Bausch Health reports its seventh consecutive quarter of year-over-year growth in both revenue and adjusted EBITDA, exceeding 2024 guidance.

Bausch + Lomb, a subsidiary of Bausch Health Companies Inc., has entered into an agreement for $400 million in new term loans to repay existing debt and for general corporate purposes.

Bausch Health announced its third quarter 2024 results, showcasing a sixth consecutive quarter of year-over-year growth in both revenue and adjusted EBITDA, and raised its full-year 2024 guidance.

Bausch Health announced a strong second quarter with revenue up 11% and adjusted EBITDA up 10%, leading to an increase in full-year guidance.

Bausch Health has appointed Jean-Jacques Charhon as its new Chief Financial Officer and Aimee Lenar as Executive Vice President, US Pharma, effective August 19, 2024 and July 15, 2024 respectively.

Bausch Health Companies Inc. held its Annual Meeting of Shareholders on May 14, 2024, where shareholders voted on key proposals including the election of directors, executive compensation, and an amendment to the company's incentive plan.

Bausch Health announced a strong first quarter of 2024 with revenue up 11% and adjusted EBITDA up 13%, marking the fourth consecutive quarter of year-over-year growth.

Bausch Health announced a 10% increase in fourth-quarter revenue and an 8% increase in full-year revenue, driven by growth across multiple segments.

Bausch Health is nominating two new independent directors, Christian A. Garcia and Frank D. Lee, while Russel C. Robertson and Thomas W. Ross, Sr. will retire from the board at the 2024 annual meeting.